ML-299 is a dual inhibitor of the two mammalian forms of phospholipase D (PLD), PLD₁ and PLD₂ (IC₅₀s = 6 and 20 nM, respectively).¹ It dose-dependently decreases the invasive migration of U98-MG glioblastoma cells into matrigel.¹ ML-299 penetrates the central nervous system and is functional in vivo when given intraperitoneally.² As PLD₁ and PLD₂ have roles in cancer and viral infection, ML-299 has potential applications in oncology and virology.²

≥95%

Store at -20℃

1.O’Reilly, M.C.,Scott, S.A.,Brown, K.A., et al. Development of dual PLD₁/2 and PLD₂ selective inhibitors from a common 1,3,8-triazaspiro[4.5]decane core: Discovery of ML298 and ML299 that decrease invasive migration in U87-MG glioblastoma cells. Journal of Medicinal Chemistry 56(6), 2695-2699 (2013).

2.Scott, S.A.,O’Reilly, M.C.,Daniels, J.S., et al. Development of a selective, allosteric PLD₁/2 inhibitor in a novel scaffold. P01 ES013125, 1-4 (2013).